tbuckley/cabot-search huggingface dataset:
Abstract 16493: Variation in Patient Characteristics Does Not Explain Regional Differences in Outcomes: Findings From ARISTOTLE
Authors: Maria Cecilia Bahit, Christopher B Granger, John H Alexander, Hillary Mulder, Daniel Wojdyla, Michael Hanna, Shinya Goto, Denis Xavier, Freek W Verheugt, Fernando Lanas, Lars Wallentin, Renato D Lopes
Journal: Circulation (2017)

Background: Variation in patient characteristics and medical practice may influence outcomes at a regional level. We sought to describe differences in demographics, practice patterns, and outcomes of patients enrolled in the ARISTOTLE trial by region of the world (North America [NA], Latin America [LA], Europe, Asia Pacific [AP]). Methods: Baseline clinical characteristics, medication use, procedures, and clinical outcomes were assessed in the 18201 patients with AF included in the ARISTOTLE trial. Results: Patients were younger in AP and older in NA. Women were more commonly included in LA. Coronary artery disease was more prevalent in Europe with the lowest prevalence being in LA. AP had highest rate of prior stroke and renal impairment (25%). Use of amiodarone and digoxin were higher in LA. More than 50% of patients in NA were taking ≥9 concomitant drugs at randomization, compared with only 10% in LA. Temporary discontinuation of study drug was highest in NA, along with an increased rate of procedures ...
Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy
Authors: Hassan Sibai, Ruiqi Chen, Xing Liu, Aaron D Schimmer, Andre Schuh, Arjun Law, Caroline J McNamara, Dawn Maze, Karen W.L. Yee, Mark D. Minden, Steven M Chan, Vikas Gupta, Tracy Murphy, Umberto Falcone, Naoko Sakurai, Joseph M. Brandwein, Jack Seki
Journal: Blood (2018)
Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease
Authors: Craig M. Riley, Frank C. Sciurba
Journal: JAMA (2019)

There are 30 million adults (12%) in the United States who have chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease accounts for 3.2% of all physician office visits annually and is the fourth leading cause of death (126 000 deaths per year). Most patients are diagnosed by their primary care clinicians who must address the highly variable clinical features and responses to therapy. The diagnosis and treatment of COPD is rapidly changing, so understanding recent advances is important for the delivery of optimal patient care.Chronic obstructive pulmonary disease is characterized by incompletely reversible expiratory airflow limitation. Spirometry is the reference standard for diagnosing and assessing the severity of COPD. All patients should be counseled about and receive preventive measures such as smoking cessation and vaccination. Treatment should be guided by the severity of lung impairment, symptoms such as dyspnea, the amount of cough and sputum production, and how often a patient experiences an exacerbation. When dyspnea limits activity or quality of life, COPD should be treated with once- or twice-daily maintenance long-acting anticholinergic and β-agonist bronchodilators. Patients with acute exacerbations may benefit from the addition of inhaled corticosteroids, particularly those with elevated peripheral eosinophil levels. Pulmonary rehabilitation, which includes strength and endurance training and educational, nutritional, and psychosocial support, improves symptoms and exercise tolerance but is underutilized. Supplemental oxygen for patients with resting hypoxemia (defined as Spo2 <89%) improves survival.Chronic obstructive pulmonary disease is a complicated disease requiring intensive treatment. Appropriate use of long-acting maintenance bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation decreases symptoms, optimizes functional performance, and reduces exacerbation frequency. Supplemental oxygen in patients with resting hypoxemia prolongs life, and other advanced treatments are available based on specific patient characteristics.
A Systematic Review and Meta-Analysis: Efficacy and Toxicity Profile of Ixazomib for Treatment of Multiple Myeloma
Authors: Madeeha Shafqat, Faiza Jamil, Zunairah Shah, Ali Younas Khan, Seren Durer, Ceren Durer, Shehroz Aslam, Insija Ilyas Selene, Anum Qureshi, Muhammad Abu Zar, Syed Shabee Hassan, Jemin Aby Jose, Warda Faridi, Faiz Anwer
Journal: Blood (2018)
Information for Readers
Authors: Elaine S. Williams
Journal: JAMA (1993)

We hereby thank the 2927 peer reviewers who completed<i>JAMA</i>article reviews in 1992 and whose names appear on pages 1321-1327. Our efforts to make the process more efficient have again resulted in stable or reduced median turnaround times. In 1992, it took a median of 12 calendar days from manuscript receipt to rejection; 81 days from receipt to acceptance; and 162 days from receipt to publication. Of this time, a mean of 26 days was required for the peer reviewers; each reviewer handled a mean of 1.9 manuscripts. Forty-six percent of manuscripts were sent for outside review, most often to three reviewers. Forty-seven percent of manuscripts were rejected without outside review, and 6% were accepted without outside review (mostly invited editorials and cover stories). The total acceptance rate for major manuscripts in 1992 was 17.5%, and the acceptance rate for unsolicited manuscripts was 11.3%. Please see p 1321 for
Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications
Authors: Eugenio Morelli, Mariateresa Fulciniti, Mehmet Kemal Samur, Francesca Scionti, Annamaria Gulla, Nicola Amodio, Giada Bianchi, Tommaso Perini, Cinzia Federico, Michael A Lopez, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone, Kenneth Anderson, Nikhil Munshi
Journal: Blood (2018)
Identification of atheroprone shear stress responsive regulatory elements in endothelial cells
Authors: Olga Bondareva, Roman Tsaryk, Vesna Bojovic, Maria Odenthal-Schnittler, Arndt F Siekmann, Hans-J Schnittler
Journal: Cardiovascular Research (2019)

Oscillatory shear stress (OSS) is an atheroprone haemodynamic force that occurs in areas of vessel irregularities and is implicated in the pathogenesis of atherosclerosis. Changes in signalling and transcriptional programme in response to OSS have been vigorously studied; however, the underlying changes in the chromatin landscape controlling transcription remain to be elucidated. Here, we investigated the changes in the regulatory element (RE) landscape of endothelial cells under atheroprone OSS conditions in an in vitro model.Analyses of H3K27ac chromatin immunoprecipitation-Seq enrichment and RNA-Seq in primary human umbilical vein endothelial cells 6 h after onset of OSS identified 2806 differential responsive REs and 33 differentially expressed genes compared with control cells kept under static conditions. Furthermore, gene ontology analyses of putative RE-associated genes uncovered enrichment of WNT/HIPPO pathway and cytoskeleton reorganization signatures. Transcription factor (TF) binding motif analysis within RE sequences identified over-representation of ETS, Zinc finger, and activator protein 1 TF families that regulate cell cycle, proliferation, and apoptosis, implicating them in the development of atherosclerosis. Importantly, we confirmed the activation of EGR1 as well as the YAP/TAZ complex early (6 h) after onset of OSS in both cultured human vein and artery endothelial cells and, by undertaking luciferase assays, functionally verified their role in RE activation in response to OSS.Based on the identification and verification of specific responsive REs early upon OSS exposure, we propose an expanded mechanism of how OSS might contribute to the development of atherosclerosis.
Association of the 36-Item Short Form Health Survey Physical Component Summary Score With Patient Satisfaction and Improvement 2 Years After Total Knee Arthroplasty
Authors: Bryon Jun Xiong Teo, Joyce Suang Bee Koh, Lei Jiang, John Carson Allen, Seng Jin Yeo, Tet Sen Howe
Journal: JAMA Network Open (2019)

Increases in total knee arthroplasty (TKA) utilization rates suggest that its indications have been expanded to include patients with less severe symptoms. A recent study challenged the cost-effectiveness of TKA in this group of patients.To determine the association of the 36-Item Short Form Health Survey physical component summary score (SF-36 PCS) with patient satisfaction 2 years after TKA.This cohort study reviewed registry data from 2 years of follow-up of patients who underwent unilateral TKA from January 1, 2010, to December 31, 2014, at a single-center tertiary institution in Singapore. Data were acquired on April 27, 2017, and analyzed from August 15, 2017, to December 22, 2017.Patient satisfaction and SF-36 PCS. Preoperative disability and postoperative function as measured by the SF-36 PCS were correlated with Δ (2-year end point score minus baseline score) and patient satisfaction, scored on a 6-point Likert scale, with lower scores indicating greater satisfaction.Of the 6659 patients, 5234 (78.6%) were female and 5753 (86.4%) were of Chinese ethnicity. Mean (SD) age was 67.0 (7.7) years, and mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 27.7 (4.6). At 2-year follow-up, the mean (SD) SF-36 PCS score improved from 32.2 (10.1) to 48.2 (9.5) (P < .001). There were 1680 patients (25.2%) who described their satisfaction as excellent, 2574 (38.7%) very good, 1879 (28.2%) good, 382 (5.7%) fair, 96 (1.4%) poor, and 48 (0.7%) terrible. The minimal clinically important difference (change in SF-36 PCS of 10 from baseline) was met in 4515 patients (67.8%), and overall satisfaction was 97.8% (6515 patients). Covariance analysis showed significantly higher satisfaction in patients with preoperative scores of 40 to less than 50. Patients who were unlikely to meet the minimal clinically important difference compared with those who were likely to meet it (SF-36 PCS of ≥42.1 vs <42.1) had significantly higher 2-year satisfaction (mean [SD], 2.15 [0.9] vs 2.23 [1.0]; P = .009).The findings suggest that a general health score, such as SF-36, is not associated with patient satisfaction 2 years after TKA. Functional assessment, preoperative counseling, and modification of expectations appear to remain vital before TKA.
Abstracts from the Emerging Science Series, June 19, 2013
Authors: Stella Aslibekyan, Marguerite Irvin, Jin Sha, Degui Zhi, Krista Thibeault, Michael Tsai, Jose Ordovas
Journal: Circulation (2013)

About the SeriesThe AHA recognizes that important scientific results do not always conveniently coincide with the timing of AHA Scientific Sessions each November.The AHA Emerging Science Series addresses this by providing 1-hour Webinars that are held 2 to 3 times a year.Each 1-hour session has two, 30-minute blocks.Each block consists of presentations of original research from the following categories:• Late-Breaking Clinical Trials • Clinical Trial Updates of previously presented Late-Breaking Clinical Trials • Late-Breaking Basic Science • Major Bench to Bedside
Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone: Results from the Phase 3 Endeavor Study According to Age Subgroup
Authors: Ruben Niesvizky, Heinz Ludwig, Andrew Spencer, Hartmut Goldschmidt, Tomas Pika, Maria-Victoria Mateos, Meletios A. Dimopoulos, Lifen Zhou, Amy S. Kimball, Thierry Facon
Journal: Blood (2017)
Publisher Correction: Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA
Authors: Jinglan Zhang, Jianli Li, Jennifer B. Saucier, Yanming Feng, Yanjun Jiang, Jefferson Sinson, Anne K. McCombs, Eric S. Schmitt, Sandra Peacock, Stella Chen, Hongzheng Dai, Xiaoyan Ge, Guoli Wang, Chad A. Shaw, Hui Mei, Amy Breman, Fan Xia, Yaping Yang, Anne Purgason, Alan Pourpak, Zhao Chen, Xia Wang, Yue Wang, Shashikant Kulkarni, Kwong Wai Choy, Ronald J. Wapner, Ignatia B. Van den Veyver, Arthur Beaudet, Sheetal Parmar, Lee-Jun Wong, Christine M. Eng
Journal: Nature Medicine (2019)
Long Noncoding RNA Loup Interacts with Runx1 and Regulates Long-Range Transcription of PU.1 in Acute Myeloid Leukemia
Authors: Bon Q Trinh, Pu Zhang, Alexander Ebralidze, Junyan Zhang, Chan-Shuo Guo, Abby Thurm, Henry Yang, Ying Li, Annalisa Di Ruscio, Daniel G. Tenen
Journal: Blood (2018)
Abstract 12349: Influenza B-Induced Fulminant Myocarditis Leading to Cardiogenic Shock
Authors: Syed Rafay Ali Sabzwari, Kailyn Mann, Hiwot Ayele, James Kimber, James Burke
Journal: Circulation (2018)

Introduction: A significant association between myocarditis and influenza A virus infection was seen in the 1918 influenza pandemic. However, since then the link between influenza B virus and fulmi...
Evaluation of IL-33 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)
Authors: Marina Petrovic, Ivan Cekerevac, Zorica Lazic, Vojislav Cupurdija, Dejan Petrovic, Rada Vucic, Gordana Kostic
Journal: European Respiratory Journal (2014)

AIM: To study the relationship between the interleukin-33 (IL-33) level in serum and broncheoalveolar lavage fluid (BALF) and non-small cell lung cancer (NSCLC).

METHODS: The concentration of IL-33 in serum or BALF of 96 NSCLC patients, 47 patients of pulmonary inflammatory diseases (PID) and 32 normal controls were measured by ELISA.

RESULTS: The concentration of IL-33 in BALF of NSCLC patients was significantly higher than that of PID patients and normal controls (P 0.05). Serum IL-33 level was higher in NSCLC of advanced stages (stage IIIa, IIIb and IV), as compared with that in NSCLC patients of early stages (stage Ia-IIb). BALF IL-33 level of NSCLC patients at different stages was not different. IL-33 (level in serum but not in BALF) of PID patients correlated with the serum concentration of C reactive protein (r=0.72).

CONCLUSION: IL-33 in BALF might be used as a marker for NSCLC. Serum IL-33 level might be an indicator for the stage of NSCLC. The serum IL-33 can also reflect the severity of acute lung inflammatory response.

Key words: non-small cell lung cancer, interleukin-33, bronchoalveolar lavage.
Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero
Authors: Hasan Satış, Reyhan Bilici Salman, Aslihan Avanoğlu Güler, Hazan Karadeniz, Şeyma Yıldız, Neslihan Kayahan
Journal: Annals of the Rheumatic Diseases (2019)

Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in uteroWe read with great interest the article 'Comorbidity and Long-Term Outcome in Patients with Congenital Heart Block and Their Siblings Exposed to Ro/SSA Autoantibodies In Utero' by Mofors et al. 1 A large and long-term follow-up population consisting of patients with congenital heart block (CHB) as a result of in utero Ro/SSA autoantibody exposure were studied.It contributes valuable information to our knowledge; however, some aspects need to be clarified and discussed.First, there was no information related to treatment during the in utero period.3][4] Especially, the combination of fluorinated steroids with IVIG improved the condition of patients with neonatal lupus-associated cardiomyopathy. 2 5Whether patients were screened and given treatment during the pregnancy period is not stated in the study.With regard to the long follow-up period, it must be considered that these treatment modalities were not available during this period.However, it may have been the reason for some patients having cardiomyopathy on follow-up.Second, at the beginning of the study, patients with CHB were included, but on follow-up, 97% of the patients had an International Classification of Diseases (ICD) code consistent with CHB diagnosis.The difference can be explained by ICD9-10 conversion.We would like to know if there is any headling patient, so such a difference has emerged.We appreciate the work of Mofors et al to highlight the prognosis of this rare condition.We believe that this comprehensive study will help us understand better the potential risk of CHB and manage these patient groups.
Influenza Vaccination Coverage Among Health Care Personnel — United States, 2014–15 Influenza Season
Authors: Carla L. Black, Xin Yue, Sarah W. Ball, Sara M.A. Donahue, David Izrael, Marie A. de Perio, A. Scott Laney, Walter W. Williams, Megan C. Lindley, Samuel B. Graitcer, Peng-jun Lu, Carolyn B. Bridges, Charles DiSogra, John Sokolowski, Deborah K. Walker, Stacie M. Greby
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

The Advisory Committee on Immunization Practices recommends annual influenza vaccination for all health care personnel (HCP) to reduce influenza-related morbidity and mortality among both HCP and their patients and to decrease absenteeism among HCP. To estimate influenza vaccination coverage among U.S. HCP for the 2014–15 influenza season, CDC conducted an opt-in Internet panel survey of 1,914 HCP during March 31–April 15, 2015. Overall, 77.3% of HCP survey participants reported receiving an influenza vaccination during the 2014–15 season, similar to the 75.2% coverage among HCP reported for the 2013–14 season. Vaccination coverage was highest among HCP working in hospitals (90.4%) and lowest among HCP working in long-term care (LTC) settings (63.9%). By occupation, coverage was highest among pharmacists (95.3%) and lowest among assistants and aides (64.4%). Influenza vaccination coverage was highest among HCP who were required by their employer to be vaccinated (96.0%). Among HCP without an employer requirement for vaccination, coverage was higher for HCP working in settings where vaccination was offered on-site at no cost for 1 day (73.6%) or multiple days (83.9%) and lowest among HCP working in settings where vaccine was neither required, promoted, nor offered on-site (44.0%). Comprehensive vaccination strategies that include making vaccine available at no cost at the workplace along with active promotion of vaccination might help increase vaccination coverage among HCP and reduce the risk for influenza to HCP and their patients.
Structural differences in the diaphragm of patients following controlled vs assisted and spontaneous mechanical ventilation
Authors: J. Marin-Corral, I. Dot, M. Boguña, L. Cecchini, A. Zapatero, M. P. Gracia, S. Pascual-Guardia, C. Vilà, A. Castellví, P. Pérez-Terán, J. Gea, J. R. Masclans
Journal: Intensive Care Medicine (2019)
<i>Notes from the Field:</i> Human <i>Brucella abortus</i> RB51 Infections Caused by Consumption of Unpasteurized Domestic Dairy Products — United States, 2017–2019
Authors: María E. Negrón, Grishma A. Kharod, William A. Bower, Henry Walke
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Since August 2017, CDC has confirmed three cases of brucellosis attributed to Brucella abortus cattle vaccine strain RB51. Each case was associated with consumption of domestically acquired unpasteurized (raw) milk products.
Abstract 18872: Knockout of Card9 Rescues Transverse Aortic Constriction Induced Contractile Dysfunction in Isolated Cardiomyocytes
Authors: Matthew R Peterson, Samantha Haller, Luiza M Bosch, Aspen Smith, Alyssa J Sanders, Guanglong He
Journal: Circulation (2017)

Introduction: CARD9, a scaffolding protein expressed in myeloid cells, regulates inflammatory cytokine secretion. Macrophage and neutrophil related inflammation is an underlying factor in cardiovas...
2018 Health Care &amp; Education Presidential Address: The American Diabetes Association in the Era of Health Care Transformation
Authors: Felicia Hill-Briggs
Journal: Diabetes Care (2019)

This address was delivered by Felicia Hill-Briggs, PhD, ABPP, President, Health Care &amp; Education of the American Diabetes Association (ADA) at the ADA’s 78th Scientific Sessions in Orlando, FL, on 23 June 2018. Diabetes has become a high-priority condition in the current era of health care transformation due to diabetes and prediabetes prevalence rates, suboptimal diabetes outcomes at the health care system and population levels, and high health care and public health costs attributed to diabetes. Population health is the path forward for the ADA to facilitate diabetes health care and public health improvement nationally. Population health management initiatives underway at the ADA include Diabetes INSIDE for health care systems and a Mental Health Provider Training Program and referral directory. Population health improvement initiatives include the prediabetes Risk Test Campaign, National Diabetes Prevention Program (DPP) dissemination in underserved states and populations, a DPP Express information technology platform, and a social determinants of health scientific review and recommendations. Dr. Hill-Briggs is a professor of medicine; physical medicine and rehabilitation; health, behavior, and society; and acute and chronic care at Johns Hopkins University in Baltimore, MD. She is a core faculty member of the Welch Center for Prevention, Epidemiology &amp; Clinical Research and colead of behavioral, social, and systems science for the Johns Hopkins Institute for Clinical and Translational Research. Dr. Hill-Briggs has been elected to the National Academy of Medicine of The National Academies of Science, Engineering, and Medicine and is the 2018 recipient of the Rachmiel Levine Medal for Leadership from the ADA.
Update in Diffuse Parenchymal Lung Disease 2012
Authors: Moisés Selman, Annie Pardo
Journal: American Journal of Respiratory and Critical Care Medicine (2013)

In 2012, relevant articles were published in the area of diffuse parenchymal lung diseases (DPLDs). Most of them were focused on idiopathic pulmonary fibrosis (IPF), the most aggressive DPLD, others on sarcoidosis, and some on less common disorders such as lymphangioleiomyomatosis. Studies in IPF revealed novel pathogenic mechanisms, putative biomarkers to predict outcome, and recently completed clinical trials, whereas in sarcoidosis most studies dealt with the identification of gene variants associated with increased risk. The concept of subclinical interstitial lung disease (ILD), meaning the presence of functional restriction or chest tomographic abnormalities in asymptomatic subjects, was underlined by two population-based studies, and our journal housed an important debate on the clinically meaningful endpoints needed to evaluate the treatment of IPF. This update highlights the advancesmade over the past year, primarily focused on those published in this journal.